Citadel Advisors
OREX

Citadel Advisors’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Citadel Advisors’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-20,920
Closed -$51.1K – 8581
2017
Q2 		$61K Buy
+20,920
New +$62.8K ﹤0.01% 7053
2016
Q3 		– Sell
-81,256
Closed -$349K – 8355
2016
Q2 		$349K Buy
81,256
+79,141
+3,742% +$358K ﹤0.01% 4999
2016
Q1 		$12K Buy
2,115
+964
+84% +$12.5K ﹤0.01% 6586
2015
Q4 		$20K Sell
1,151
-15,707
-93% -$375K ﹤0.01% 7951
2015
Q3 		$356K Buy
16,858
+6,671
+65% +$229K ﹤0.01% 5310
2015
Q2 		$504K Buy
10,187
+5,943
+140% +$355K ﹤0.01% 4962
2015
Q1 		$332K Sell
4,244
-16,124
-79% -$1M ﹤0.01% 5503
2014
Q4 		$1.24M Buy
20,368
+13,453
+195% +$676K ﹤0.01% 3503
2014
Q3 		$295K Buy
6,915
+1,621
+31% +$87K ﹤0.01% 5281
2014
Q2 		$327K Buy
5,294
+620
+13% +$36.1K ﹤0.01% 4948
2014
Q1 		$304K Sell
4,674
-2,264
-33% -$153K ﹤0.01% 5006
2013
Q4 		$391K Sell
6,938
-127,598
-95% -$7.17M ﹤0.01% 4301
2013
Q3 		$8.26M Buy
134,536
+32,956
+32% +$2.23M 0.01% 1225
2013
Q2 		$5.94M Buy
+101,580
New +$6.25M 0.01% 1411

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
OWIM
Old West Investment Management Los Angeles, California $923M AUM 112.31% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Citadel Advisors's OREX Position: Q3 2017 in Review

Citadel Advisors sold out of Orexigen Therapeutics, Inc. (OREX) in Q3 2017, closing a stake of 20,920 shares — an estimated $51.1K sold.

Citadel Advisors first reported a position in OREX in Q2 2013 and held it in 14 quarters. The position peaked at $8.26M in Q3 2013. 42 funds tracked by Wall St. Rank hold OREX as of Q3 2017.

  • Citadel Advisors reported no remaining Orexigen Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
  • Citadel Advisors sold 20,920 Orexigen Therapeutics, Inc. shares in Q3 2017, an estimated $51.1K.
  • Citadel Advisors first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 14 quarters.
  • Citadel Advisors's Orexigen Therapeutics, Inc. position peaked at $8.26M in Q3 2013.
  • 42 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q3 2017.

Based on Citadel Advisors's 13F filing for Q3 2017, filed 9 Nov 2017.